Clinical use of biomarkers in the field of cytotoxic nucleoside analogues
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical use of biomarkers in the field of cytotoxic nucleoside analogues
Authors
Keywords
-
Journal
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2023-10-24
DOI
10.1080/15257770.2023.2272640
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine
- (2023) Liang Zhang et al. Journal of Medicinal Chemistry
- Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation
- (2022) Abdelrahman H. Elsayed et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
- (2021) Farasat Kazmi et al. CLINICAL CANCER RESEARCH
- RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
- (2021) Wendy Muñoz-Montaño et al. BMC CANCER
- Molecular imaging of deoxycytidine kinase activity using deoxycytidine-enhanced CEST MRI
- (2019) Zheng Han et al. CANCER RESEARCH
- Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
- (2018) Sarah P. Blagden et al. BRITISH JOURNAL OF CANCER
- Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study
- (2018) Carmelo Tibaldi et al. BRITISH JOURNAL OF CANCER
- Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy
- (2017) Toru Aoyama et al. Oncology Letters
- Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
- (2013) Lars Petter Jordheim et al. NATURE REVIEWS DRUG DISCOVERY
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection
- (2012) Naoya Nakagawa et al. SURGERY
- Design, Synthesis, and Evaluation of 2-Diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein Conjugate (8MDP-fluor), As a Novel Equilibrative Nucleoside Transporter Probe
- (2011) Wenwei Lin et al. BIOCONJUGATE CHEMISTRY
- The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
- (2010) Lars Petter Jordheim et al. LANCET ONCOLOGY
- The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)
- (2010) Jae Jin Lee et al. LUNG CANCER
- Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies
- (2009) Joseph Ciccolini et al. JOURNAL OF CLINICAL ONCOLOGY
- Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography
- (2009) Rachel E. Laing et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started